Neuphoria Therapeutics Inc. – Common Stock (NASDAQ:NEUP – Free Report) – Research analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Neuphoria Therapeutics Inc. – Common Stock in a report issued on Tuesday, February 4th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($1.21) for the year. HC Wainwright currently has a “Buy” rating and a $21.00 target price on the stock. HC Wainwright also issued estimates for Neuphoria Therapeutics Inc. – Common Stock’s FY2028 earnings at ($1.36) EPS.
Neuphoria Therapeutics Inc. – Common Stock Stock Performance
NASDAQ NEUP opened at $5.09 on Wednesday. Neuphoria Therapeutics Inc. – Common Stock has a 1-year low of $2.12 and a 1-year high of $16.08.
About Neuphoria Therapeutics Inc. – Common Stock
Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Read More
- Five stocks we like better than Neuphoria Therapeutics Inc. – Common Stock
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Market Volatility Creates Opportunity in These 3 Value Stocks
- Why Invest in High-Yield Dividend Stocks?
- Visa and Mastercard Remain Strong Plays as Consumers Keep Swiping
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 2 High-Yield Consumer Staples Stocks Ready to Deliver Big Returns
Receive News & Ratings for Neuphoria Therapeutics Inc. - Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuphoria Therapeutics Inc. - Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
